Home›Trial›NCT05539430
🔬NCT05539430Phase 1ACTIVE NOT RECRUITING

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Study Summary

This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Conditions
Gastric CancerGastroesophageal-junction CancerEsophageal CancerPancreatic Cancer
Interventions / Drugs
LB1908
View on ClinicalTrials.gov ↗
Sponsor
LEGN
Legend Biotech
Oncology
F15/100
Study Details
Enrollment56 participants
Primary Completion—
Lead SponsorLegend Biotech USA Inc
Data Retrieved2026-04-11 04:19:29.745708+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.